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Abstract
Aims Despite previous surveys regarding device implantation rates in heart failure (HF), insight into the real-world manage-
ment with devices is scarce. Therefore, we investigated device implantation rates in HF with reduced left ventricular ejection
fraction (LVEF) in 34 Dutch centres.
Methods and results A cross-sectional outpatient registry was conducted in 6666 patients with LVEF < 50% and with infor-
mation about device implantation available [74 (66–81) years of age; 64% male]. Patients were classified into conventional
pacemakers (PM, n = 562), implantable cardioverter defibrillators (ICD, n = 1165), and cardiac resynchronization therapy with
defibrillator function (CRT-D, n = 885) or pacemaker function only (CRT-P, n = 248), or no device (n = 3806). Centres were di-
vided into ICD-implanting and CRT-implanting and referral centres. Overall, 17.5% had an ICD, 13.3% CRT-D, 3.7% CRT-P, and
8.4% PM. Of those with LVEF ≤ 30%, 42.5% had ICD or CRT-D therapy. A large variation in implantation rates existed between
centres: 3–51% for ICD therapy, 0.3–44% for CRT-D therapy, 0–11% for CRT-P therapy, and 0–25% PM therapy. Implantation
centres showed higher implantation rates of ICD, CRT-D, and CRT-P compared with referral centres [36% vs. 25% for defibril-
lators (ICD or CRT-D) and 17% vs. 9% for CRT devices (CRT-D or CRT-P), respectively, P < 0.001], independently of other fac-
tors. A large number of clinical factors were predictive for device usage. Among other, LVEF < 40% and male sex were
independent positive predictors for ICD/CRT-D use [odds ratio (OR) = 3.33, P< 0.001; OR = 1.87, P = 0.019, respectively]. Older
age was independently associated with less ICD/CRT-D (OR = 0.96 per year, P < 0.001) and more CRT-P/PM use (OR = 1.03 per
year, P = 0.006).
Conclusions In this large Dutch HF registry, less than half of the patients with reduced LVEF received an ICD or CRT, even if
LVEF was ≤30%, and a large variation between centres existed. Patients from implantation centres had more often ICD or CRT.
More uniformity regarding guideline-based use of device therapy in clinical practice is needed.
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Introduction
Prognosis worsens when chronic heart failure (HF) remains
untreated or when it is treated insufficiently; accordingly,
physicians’ adherence to treatment guidelines is a strong pre-
dictor of better prognosis (1,2). Nevertheless, suboptimal
treatment is often present though not well recognized (3,4).
Explanatory factors influencing the decision making of physi-
cians regarding HF treatment have not been sufficiently stud-
ied. Both in Europe and in the USA, large regional variations
exist in the use of HF medication (5,6), and this may also ap-
ply to the use of device therapy (7). Despite the fact that HF
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guidelines are similar in Europe, Eastern European countries
showed a significantly lower implantation rate of implantable
cardioverter defibrillators (ICD) and/or cardiac
resynchronization therapy (CRT) (7,8). Besides regional differ-
ences, significant inequalities have been shown for race and
sex: particularly women and minority patients received less
often ICDs despite eligibility according to international HF
guidelines (9). Device therapy rates are lower in elderly pa-
tients despite the fact that guidelines recommend device
therapy regardless of age (10–12).
Recent surveys found rising implantation rates of ICDs and
CRT over the past decade. However, the absolute use re-
mains poor (13–15). However, patients in these surveys were
often not representative to the real-world HF population and
were younger than those in clinical practice (14–16). In addi-
tion, only tertiary centres were included, and HF patients
with co-morbidities were excluded in some surveys (14,17).
To gain more insight into the real-world contemporary
management of device therapy in patients with chronic HF
and reduced left ventricular ejection fraction (LVEF), we per-
formed a cross-sectional study of contemporary HF care re-
garding device therapy, using the CHECK-HF (Chronisch
Hartfalen ESC-richtlijn Cardiologische praktijk
Kwaliteitsproject HartFalen) registry that consists of more
than 10 000 HF patients seen at HF outpatient clinics in the
Netherlands. Because basically all patients in the
Netherlands are seen at the outpatient clinic of hospitals
and not in private practices, and no further exclusion criteria
were applied, this HF population is representative for the
real-world management of patients with chronic HF.
Methods
The methods of the CHECK-HF (Chronisch Hartfalen
ESC-richtlijn Cardiologische praktijk Kwaliteitsproject
HartFalen) registry have been published earlier (18). HF out-
patient clinics were invited to participate in this registry. In
total, 34 Dutch centres participated over a period of 3 years
(2013–2016). They were asked to include all current HF pa-
tients cross-sectionally. The centres included between 37
and 2529 patients (median 240, interquartile range 154–320
patients). The major inclusion criterion was presence of diag-
nosis of HF, based on the most recent ESC guidelines criteria
at time of inclusion (19). Information on patient characteris-
tics, main cause of HF, basic echocardiographic and electro-
cardiographic measurements, co-morbidities, and some
laboratory results were recorded. This study was conducted
according to the Declaration of Helsinki. Ethical approval
was provided for anonymously analysing existing patient data
by the Ethical Committee of the Maastricht University Medi-
cal Centre, the Netherlands. All patients provided informed
consent. Patients were divided into HF with preserved
ejection fraction (HFpEF) defined as HF symptoms,
LVEF ≥ 50% and signs of structural or functional cardiac ab-
normalities and not having any known history of LVEF < 50%,
and patients HF with reduced ejection fraction (LVEF < 50%).
Only the latter group was included in this study and was fur-
ther divided into two groups based on the most recent guide-
lines (5,11): HFmrEF (LVEF 40–49%) and HFrEF (LVEF < 40%)
in supplementary analyses. In some patients, reduced LVEF
was only known semi-quantitatively, which are shown sepa-
rately. Because of lack of information on LVEF, 283 patients
were excluded. Patients were classified according to im-
planted devices into the following groups: conventional single
or dual chamber pacemakers (PM), ICD, cardiac
resynchronization therapy with defibrillator function (CRT-D)
or with pacemaker function only (CRT-P), or no implanted de-
vice. Centres were divided into those that implant ICD and
CRT devices (implantation centres) and those that only im-
plant conventional PM (referral centres). No centre did not
implant any device.
Statistics
Results are presented as frequencies (%), mean (± standard
deviation), or median (interquartile range), as appropriate.
Between-group comparisons were performed using the inde-
pendent samples T-test, Mann–Whitney U test, the one-way
analyses of variance, Kruskal–Wallis H-test, or Pearson χ2, as
appropriate. Multivariable predictors of device therapy were
sought using binary logistic regression analysis, using the
stepwise backward procedure (inclusion at P < 0.05, exclu-
sion at P > 0.10). All variables with P < 0.2 at baseline were
included for multivariable analysis. Using the stepwise for-
ward procedure or simply entering all variables into equation
did not result in clinically meaningful differences (data not
shown). As preimplantation values are not known, QRS dura-
tion was not considered in these analyses. Results of logistic
expression are presented as odds ratio and level of signifi-
cance. A two-sided alpha of 0.05 was considered to be statis-
tically significant. All calculations were performed with the
use of the SPSS statistical package version 25.0 (SPSS Inc, Chi-
cago, Illinois).
Results
Of the 10 910 patients included in the CHECK-HF registry,
8360 patients (73.6%) had an LVEF < 50%. Of these patients,
information about the use of devices was available in 6666
patients (79.7%). Of these, 2860 patients (42.9%) had any de-
vice: 562 patients (8.4%) had a PM, 1165 (17.5%) an ICD, 885
(13.3%) a CRT-D, and 248 (3.7%) a CRT-P. Thus, 2050 patients
(30.8%) had a defibrillator implanted and 1133 (17.0%) a CRT
device. In the group of patients with known LVEF < 40%
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(HFrEF), 2231 (46.4%) had any device, compared with 316
(28.6%) of the HFmrEF patients and 313 (41.7%) of patients
with semi-quantified LVEF. When taking into account the indi-
cation according to ESC guidelines for ICD or CRT-D regarding
LVEF (LVEF ≤ 30%), 928 patients (42.5%) with LVEF ≤ 30%
(n = 2185) had either an ICD or CRT-D. The use of ICD, CRT
(CRT-D and CRT-P), and PM in HFrEF, HFmrEF,
semi-quantified LVEF, and LVEF ≤ 30% is shown in Figure 1.
Baseline characteristics of the included patients are shown
in Table 1. The mean age of the patients was 74 years, and
almost two-thirds was male. Patients with ICD or CRT-D were
younger of age, whereas patients with PM were older (Figure
2). The male predominance was significantly larger in ICD and
CRT-D patients compared with the other groups. Moreover, a
larger part of all women did not have any device in compari-
son with men (65% vs. 53% respectively, P < 0.001, Figure 3).
Ischaemic heart disease was the most common cause of HF.
Most patients were in New York Heart Association (NYHA)
functional class II, and only a few were in NYHA functional
class IV. Overall, patients with PM or CRT-P were in a higher
NYHA class; they were older and had a longer QRS duration
and slightly more co-morbidities. They also used less HF
medication, especially renin-angiotensin receptor blockers
(RAS inhibitor), beta-blockers, and mineralocorticoid receptor
antagonists (MRA) (Table 1). Use of triple therapy (meaning
beta-blocker and RAS inhibitor and MRA) was highest in
patients with ICD and CRT-D, in comparison with CRT-P,
PM, and patients without device (Supporting Information,
Figure S1).
Implantation rates between centres
Use of devices differed significantly across centres
(P < 0.001). Implantation rates of ICD varied between 3%
and 51%. Accordingly, rates for CRT-D and CRT-P were 0.3–
44% and 0–11%, respectively. Single ventricular PM implanta-
tion varied between 0% and 25% (Figure 4).
There was a significant difference in ICD and CRT implanta-
tion rates between patients from implantation centres and
referral centres [36% vs. 25% for defibrillators (i.e. ICD and
CRT-D) and 17% vs. 9% for CRT-devices (i.e. CRT-D and CRT-
P), respectively, P < 0.001]. No significant difference was
seen in patients with PM. Patients from the referring centres
were slightly older, had a higher NYHA classification, more of-
ten non-ischaemic DCM as cause for HF, more renal failure,
less hypercholesterolaemia, and underwent fewer interven-
tions. Moreover, more patients from referring centres used
HF medication than patients from implantation centres, in
particular more diuretics, beta-blockers, and MRAs
(Supporting Information, Table S1).
Predictors of device therapy
Multivariable predictors of the device usage are shown in
Table 2. Only patients with complete information on all vari-
ables were included in multivariable analyses (n = 3447).
Patients not included for multivariable analysis (n = 3219)
due to lack of some data had a slightly higher NYHA class
(NYHA functional class I was observed in 13% in the group
of excluded patients vs. 14% in the group of included pa-
tients; NYHA functional class II in 57% vs. 61%, respectively;
NYHA functional class III in 28% vs. 24%, respectively; and
NYHA functional class IV in 3% vs. 1%, respectively), had less
often no co-morbidities (26% vs. 20%, respectively), and less
often had LVEF semi-quantitatively measured (10% vs. 13%,
respectively), but the differences were relatively small and
of no clinical relevance. HFrEF was a strong predictor of ICD
and CRT use, as suspected. Age was also an independent pre-
dictor: the younger the patient, the higher the chance of hav-
ing an ICD or CRT-D implanted (Figure 2A). Meanwhile, older
patients were more likely to have a PM. This was also true for
patients with LVEF < 30% (Figure 2B). Men were more likely
to receive ICD or CRT-D therapy compared with women. An
ischaemic cause of HF including interventions such as PCI
and CABG was a strong predictor of ICD or CRT use. On the
other hand, atrial fibrillation as cause of HF was associated
with less ICD and CRT implantation. Patients with
co-morbidities were more likely to have ICD or CRT. The use
of ICD and CRT-D was significantly higher in implantation cen-
tres as compared with referral centres independently of
other variables. Time between HF diagnosis and device im-
plantation was not independently associated for the use of
ICD, CRT, or PM (Table 2).
Figure 1 Use of ICD, CRT, and PM in patients with LVEF ≤ 30%, patients
with HFrEF, patients with HFmrEF, and patients with only
semi-quantitatively measured LVEF.
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Table 1 Baseline characteristics of patients with ICD, CRT, and PM
Total
(n = 6666)
No device
(n = 3806)
ICD
(n = 1165)
CRT-D
(n = 885)
CRT-P
(n = 248)
PM
(n = 562) P-value
Age (years) (n = 6666) 74 [66–81] 75 [59–91] 68 [52–84] 70 [57–83] 78 [66–90] 81 [71–91] <0.001
Male (n = 6635) 4256 (64) 2248 (59) 883 (59) 630 (71) 155 (63) 340 (61) <0.001
BMI (kg/m2) (n = 6163) 27 ± 5 27 ± 5 28 ± 5 28 ± 5 27 ± 5 27 ± 5 0.001
Heart rate
(beats/min) (n = 6576)
71 ± 13 72 ± 14 69 ± 13 72 ± 11 72 ± 11 74 ± 12 <0.001
RR systolic (mmHg) (n = 6591) 124 ± 20 127 ± 20 121 ± 18 125 ± 20 127 ± 22 126 ± 19 <0.001
RR diastolic (mmHg) (n = 6597) 70 ± 11 72 ± 11 70 ± 11 72 ± 11 71 ± 11 70 ± 11 0.01
NYHA (n = 6599) <0.001
NYHA I 876 (13) 446 (12) 206 (18) 153 (17) 27 (11) 44 (8)
NYHA II 3872 (58) 2283 (61) 659 (57) 481 (55) 139 (57) 310 (56)
NYHA III 1727 (26) 970 (26) 266 (23) 228 (26) 75 (31) 188 (34)
NYHA IV 124 (2) 65 (2) 24 (2) 17 (2) 5 (2) 13 (2)
Oedema (n = 4914) 602 (74) 315 (12) 101 (12) 93 (13) 20 (10) 73 (16) 0.09
Euvolemic (n = 4332) 3983 (60) 2143 (93) 701 (91) 627 (92) 170 (91) 342 (88) 0.09
LVEF (n = 4946) 32 ± 10 33 ± 10 29 ± 9 29 ± 9 32 ± 10 37 ± 11 <0.001
LVEF ≤ 30% (n = 6666) 2185 (41) 1036 (49) 548 (25) 380 (17) 59 (2) 135 (6) <0.001
HFrEF (n = 6666) 4810 (72) 2579 (54) 976 (20) 735 (15) 180 (4) 340 (7) <0.001
HFmrEF (n = 6666) 1105 (17) 789 (71) 86 (8) 61 (6) 34 (3) 135 (12) <0.001
Semi-quantified
HFrEF (n = 6666)
751 (11) 438 (58) 103 (14) 89 (12) 34 (5) 87 (12) 0.001
QRS (ms) (n = 5519) 121 [100–154] 110 [69–151] 118 [75–161] 156 [114–198] 159 [122–196] 162 [98–226] <0.001
Causes of HF (n = 6455)
Ischaemic 3376 (51) 1785 (49) 787 (70) 453 (52) 107 (44) 244 (46) <0.001
Non-ischaemic DCM 1262 (19) 652 (18) 224 (20) 234 (27) 71 (29) 81 (15) <0.001
HHD 285 (4) 197 (5) 18 (2) 36 (4) 13 (5) 21 (4) <0.001
Valvular disease 987 (15) 630 (17) 133 (12) 79 (9) 23 (10) 122 (23) <0.001
AF 1310 (20) 886 (24) 133 (12) 89 (10) 31 (13) 171 (32) <0.001
Conduction 275 (4) 96 (3) 53 (5) 60 (7) 12 (5) 54 (10) <0.001
Co-morbidities (n = 6073)
Anaemia 285 (4) 142 (4) 54 (5) 46 (6) 12 (5) 31 (6) 0.052
Hypertension 2421 (36) 1462 (41) 342 (22) 296 (38) 103 (46) 218 (44) <0.001
Hypercholesterolaemia 838 (13) 420 (12) 204 (20) 126 (16) 35 (16) 53 (11) <0.001
DM type 2 1558 (23) 894 (25) 250 (24) 219 (28) 53 (24) 142 (29) 0.209
COPD 1108 (17) 677 (19) 164 (16) 135 (17) 46 (21) 86 (17) 0.098
OSAS 392 (6) 187 (5) 86 (8) 70 (9) 14 (6) 35 (7) <0.001
Hyperthyroidism 174 (3) 79 (2) 31 (3) 30 (4) 8 (4) 26 (5) 0.001
Hypothyroidism 280 (4) 135 (4) 60 (6) 37 (5) 15 (7) 33 (7) 0.004
Renal failure (eGFR
< 60 mL/min/1.73 m2)
3436 (52) 2029 (54) 526 (53) 399 (58) 131 (66) 351 (73) <0.001
PAD 423 (6) 233 (7) 92 (9) 55 (7) 15 (7) 28 (6) 0.09
No co-morbidities 1265 (19) 871 (25) 200 (23) 105 (19) 27 (16) 62 (15) <0.001
Interventions (n = 5852)
PCI 1382 (21) 673 (19) 361 (37) 220 (34) 43 (23) 85 (20) <0.001
Valvular repair/replacement 419 (6) 193 (5) 58 (6) 79 (12) 22 (12) 67 (16) <0.001
CABG 1157 (17) 539 (15) 292 (30) 183 (28) 42 (22) 101 (24) <0.001
Other 201 (3) 91 (3) 37 (4) 39 (6) 7 (4) 27 (6) <0.001
No intervention 3172 (48) 2305 (64) 352 (36) 233 (36) 90 (48) 192 (45) <0.001
Medication (n = 6666)
Diuretics 5578 (84) 3202 (84) 963 (83) 722 (82) 198 (90) 492 (88) 0.008
Statins 3493 (52) 1758 (46) 755 (65) 573 (65) 134 (54) 273 (49) <0.001
ACE-inhibitors or ARB 5318 (80) 2123 (56) 650 (56) 494 (56) 134 (54) 251 (45) <0.001
ARNI 23 (0.3)
Beta-blockers 5594 (84) 3217 (85) 1022 (88) 745 (84) 198 (80) 412 (73) <0.001
MRA 3744 (56) 2108 (55) 689 (59) 518 (59) 114 (46) 315 (56) 0.001
Ivabradin 337 (5) 192 (5) 74 (6) 45 (5) 7 (3) 19 (3) 0.04
Digoxin 1115 (17) 698 (18) 128 (11) 145 (16) 46 (19) 98 (17) <0.001
Amiodarone 653 (10) 183 (5) 204 (18) 173 (20) 33 (13) 60 (11) <0.001
Values are mean ± standard deviation, median [interquartile range], or n (%). ACE-inhibitors, angiotensin-converting enzyme inhibitors;
AF, atrial fibrillation; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysine inhibitor; BMI, body mass index; CABG,
coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; DCM, dilated cardio-
myopathy; DM, diabetes mellitus; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction (i.e. 40% to 49%); HFrEF, heart
failure with reduced ejection fraction (i.e. <40%); HHD, hypertensive heart disease; ICD, implantable cardio defibrillator; LBBB, left-bundle
branch block; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; OSAS, obstructive sleep apnoea syn-
drome; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PM, pacemaker; renal failure, either renal failure in med-
ical history or eGFR < 60 mL/min/1.73 m2; RR, blood pressure.
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Discussion
In this cross-sectional study of current device therapy in a
real-world setting of HF management, there were three main
observations. First, implantation rates of both ICD and CRTD
were lower than what could be expected from guideline rec-
ommendations (11,19), even in patients with LVEF ≤ 30%.
Second, there was great variation across centres for all types
of devices. Interestingly, implantation centres had higher ICD
and CRT implantation rates than referral centres, indepen-
dent of clinical factors. Third, there were other demographic
predictors for device therapy such as age, sex, cause of HF,
co-morbidities, and cardiac interventions.
Implantation rates have increased in recent years. A US uni-
versity centre registry showed an increase of ICD use in HF pa-
tients with LVEF ≤ 40% from 11% to 66% and CRT use from 0%
to 39%, respectively, between 1993–1995 and 2006–2009
(17). This increase in implantation rates in recent years was
seen in multiple surveys (13–15). Implantation rates from
the CHECK-HF registry were slightly higher than implantation
rates from most registries performed earlier (7,8,13,20). This
suggests that guideline adherence regarding device therapy
in HF has improved. Nevertheless, overall implantation rates
remain lower than expected. In our registry, less than half of
the HF patients with LVEF ≤ 30% received an ICD or CRTD,
which can only partly be explained by medical factors.
We found large variation in implantation rates across cen-
tres, which can be explained by medical factors only to a very
limited extent. This variation between centres has also been
observed previously in the USA (6) as well as in Europe (7). In-
deed, implantation rates varied between 0% and 80% in the
USA, for which no explanation could be found (6), which is
in line with our findings. Although there was less variation
in our study when compared with other registries, it remains
in a range unexplained by differences in patients’ characteris-
tics. Therefore, though not tested, it is likely that the way of
decision making for device implantation is not uniform, de-
spite the uniform recommendations from guidelines provided
by the ESC (11). Further, patients treated in implantation cen-
tres were significantly more likely to receive ICD and CRT
therapy, respectively, in comparison with patients treated in
referral centres. This difference was largely independent of
clinical factors. A possible explanation for this difference is
that clinicians, especially those from referral centres, focus
more on HF medication therapy and, therefore,
underappreciate the incremental value of an ICD on top of
optimal medical therapy (6,8). In our survey, more patients
from referral centres had been given HF medication in com-
parison with patients from implantation centres. It is possible
that physicians working in referral centres tend to focus on
HF medication while managing HF patients and are thus more
reluctant to refer patients to another centre for device
Figure 2 Implantation rates in different age groups. Figure 3 Sex differences in implantation rates.
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Figure 4 Variation in implantation rates across (A) all centres, (B) referral centres, and (C) implantation centres.
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therapy. In contrast, physicians working in implantation cen-
tres may apply device therapy earlier and focus somewhat
less on medical therapy. It should be noted, however, that
neither medical therapy nor device therapy was according
to the guideline recommendations in both implantation and
referral centres. This suggests that there remains room for
improvement of both medical therapy and device therapy in
basically all centres despite different focus between the two
types of centres. Unfortunately, the lack of longitudinal data
and direct knowledge of indications for different therapies
in the CHECK-HF registry makes it impossible to verify these
suggestions. Nevertheless, the findings support the notion
that the optimal treatment of patients requires special atten-
tion to the combination of device therapy, optimal medical
therapy, and other integral aspects of HF management.
The findings of the present study are in some contrast with
findings in the GWTG-HF registry, where significant positive
correlations were found between implantation rates and pre-
scription rates of HF medication (7). Centres with higher ICD
implantation rates were also more likely to adopt newer HF
therapies, leading towards higher prescription rates of rec-
ommended HF medication. This difference between the find-
ings of this and those of the GWTG-HF registry could be
explained by the fact that, on average, medical therapy in
the Dutch centres is more in concordance with guidelines
than in US centres (6,21). However, this remains speculative
as the available data do not allow to investigate causality.
As it may be suspected, the results of this registry revealed
age to be an important factor in the decision making of de-
vice therapy in HF patients. Older patients were less likely
to have ICD or CRT, in contrast to PM. ICD and CRT-D rates
were highest in patients <70 years, whereas PM rates were
highest in patients >80 years. Previous studies has shown
that the benefit of ICD therapy in terms of lifespan gain de-
creases during ageing because of the higher co-morbidity
rates (22–24). The ESC guidelines state an expected survival
of >1 year as a criterion for ICD and CRTD therapy (11). Be-
cause older patients have a lower life expectancy, in some
cases, this may be considered a contraindication for ICD or
CRT-D therapy by patient or clinician. Moreover, elderly pa-
tients may more often be rejected from implantation of a de-
fibrillator device, because of the higher peri-operative risks
and in-hospital mortality (25). However, co-morbidities seem
to be greater predictors of complication risks than age alone,
and the risk of peri-procedural complications is only slightly
increased (25). Interestingly, co-morbidities were not a pre-
dictor of less ICD or CRT, in contrast to age in the present reg-
istry. In addition, it may be assumed that increasing survival
becomes less important with increasing age. Although this
has been found in elderly HF patients, the majority of even
those aged 75 years or more still preferred longevity over
quality of life (26).
Despite the fact that guideline recommendations regard-
ing device therapy are equal for men and women (11),
women are less likely to receive ICD therapy (9,27). Previous
studies have shown that sex is an independent predictor of
receiving ICD therapy, for both primary and secondary pre-
vention (9, 27–29). This is in line with our results, where
sex was an independent predictor for ICD or CRT-D therapy,
and women were less likely to have ICD or CRT-D therapy.
Exact reasons why the implantation rates in women are
lower than in men are still unclear. This ambiguity could be
Table 2 Multivariable predictors of device therapy
N = 3447
ICD/CRT-D (n = 650) CRT-D/CRT-P (n = 547) PM/CRT-P (n = 152)
OR P-value OR P-value OR P-value
Age 0.96 <0.001 — — 1.03 0.006
Male 1.87 0.019 — — — —
RR systolic 0.99 0.017 — — — —
HFrEF 3.33 <0.001 3.56 <0.001 — —
Ischaemic HF 2.42 <0.001 — — — —
Non-ischaemic HF 1.93 <0.001 — — 2.42 0.001
Valvular HF — — 0.54 0.006 0.37 0.018
Conduction disorder caused HF 1.60 0.012 2.49 <0.001 — —
AF caused HF 0.50 <0.001 0.44 <0.001 — —
No co-morbidity 0.73 0.028 — — — —
Hypertension — — 1.36 0.030 — —
DM II — — — — 0.49 0.036
Hyperthyroidism 0.28 0.014 0.33 0.151 — —
Hypercholesterolaemia 1.51 0.001 — — — —
PCI 1.45 0.003 — — — —
CABG 1.45 0.007 — — — —
Valvular replacement — — 2.04 0.007 3.55 0.002
Other intervention 2.67 <0.001 3.24 <0.001 — —
ACE/ARB — — — — 1.87 0.090
Amiodarone 3.44 <0.001 2.46 <0.001 — —
Implantation centre 1.29 0.024 — — 0.55 0.012
Time since HF diagnosis 1.08 0.091 1.06 0.102 0.86 0.083
OR, odds ratio; other abbreviations as in Table 1.
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partly explained by the fact that, until now, only an average
of 20% of the included patients in big randomized ICD trials
is female. This fact makes it also difficult to explore potential
causes for this sex difference (30–33). Still, there are numer-
ous factors that could (partly) explain the lower implantation
rates in women. First, men more often present with ischae-
mic HF and reduced LVEF, whereas women mainly present
with non-ischaemic HF and preserved EF and are in that case
not eligible for ICD therapy (33, 34). Second, women are,
overall, older at time of presentation as compared with
men and have a greater burden of co-morbidities (35), which
may be important factors in the decision-making process.
However, even when ICD therapy or CRT-D is indicated,
men are more likely to undergo ICD or CRT-D implantation,
irrespective of other confounders such as AF, chronic kidney
disease, and age (35, 36). Third, longevity might be less im-
portant for women as compared with men (26), possibly
influencing decision making. Despite these potential factors,
the reduced implantation rate in women remains largely un-
explained, in line with the present results.
Study strengths and limitations
Because this study was conducted as a case–control design
lacking some information, we were not able to specifically de-
termine guideline adherence regarding device therapy.We are
unable to verify if patients fulfilled the indication for device
therapy according to the recommendations of the guidelines
at the moment of inclusion in the registry. For example, some
patients with reduced LVEF and no ICD or CRT-D might still be
in the phase of up titrating HF medication and may recover af-
ter optimal medical therapy (OMT). Due to the cross-sectional
nature of this registry, causality cannot be investigated. We
also do not have information on individual patient’s prefer-
ences. It is possible, particularly at older age, that patients
had contraindications for ICD use or refrained from having a
device implanted. As the data were collected at a certain
timepoint unrelated to the data of implantation, indications
for devices prior to implantation are unknown. This also in-
cludes the QRS duration or specific conduction abnormalities
prior to implantation. Because patient data were collected ret-
rospectively, based on existing patient files, some data were
missing. Despite the fact that there were not many clinically
significant differences between patients with and without
missing data, this may have influenced our results. Only
one-half of the Dutch centres with outpatient HF clinics
participated in this study, together with only one out of eight
university medical centres. Nevertheless, the percentage of
contributing centres and patients is much higher than in other
registries, which makes this registry a reasonable reflection of
contemporary HF management in the Netherlands. Moreover,
only patients in secondary care were included in this registry,
and patients only treated in primary care were not considered.
It is likely that both patient population and treatment are dif-
ferent in primary care in the Netherlands as compared with
our registry. Still, our population is a large and representative
sample of the Dutch HF patients in secondary care.
Conclusions
In a large Dutch registry of HF patients with both reduced and
mid-range LVEF, there was large variation of implantation
rates across participating centres. Referral centres used less
ICD or CRT therapy, in comparison with centre implanting
these devices. These findings suggest that better ways for
achieving uniformity regarding guideline-based use of device
therapy in clinical practice are desirable.
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